Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 14

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Hepatol. May 18, 2016; 8(14): 625-631
Published online May 18, 2016. doi: 10.4254/wjh.v8.i14.625

Full Size Figure Download Figure

Figure 2 Number of patients who became hepatitis D virus RNA negative. HDV: Hepatitis D virus; PEG-IFN: Pegylated interferon.

Citation: Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol 2016; 8(14): 625-631
URL: https://www.wjgnet.com/1948-5182/full/v8/i14/625.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i14.625

Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol 2016; 8(14): 625-631 [PMID: 27190579 DOI: 10.4254/wjh.v8.i14.625]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.